Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Cetuximab
72%
Monoclonal Antibody
53%
Malignant Neoplasm
41%
Neoplasm
26%
Breast Cancer
24%
Epidermal Growth Factor
22%
Protein Kinase B
20%
Growth Factor Receptor
18%
Phosphotransferase
18%
Hypoxia Inducible Factor 1
17%
Receptor
16%
Prostate Cancer
15%
Receptor Antibody
14%
Paclitaxel
13%
Head and Neck Squamous Cell Carcinoma
12%
Colorectal Carcinoma
11%
Protein Tyrosine Kinase
11%
Epidermal Growth Factor Receptor Antibody
10%
Gefitinib
9%
Breast Tumor
9%
Chemotherapy
7%
Cytotoxicity
7%
Doxorubicin
7%
Epidermal Growth Factor Receptor 2
7%
Cisplatin
6%
Gamma Urogastrone
6%
Androgen
6%
Caspase 8
6%
Ovary Cancer
6%
Squamous Cell Carcinoma
6%
Trastuzumab
6%
Phosphatidylinositol 3 Kinase
6%
Macrogol
5%
Chimeric Protein
5%
Antitumor Activity
5%
Liver Cell Carcinoma
5%
Mitogen Activated Protein Kinase
5%
Epidermal Growth Factor Receptor Kinase Inhibitor
5%
Ionizing Radiation
5%
Cyclin Dependent Kinase 2
5%
Keyphrases
Epidermal Growth Factor Receptor
42%
Cetuximab
32%
Anti-epidermal Growth Factor Receptor Monoclonal Antibodies
30%
Breast Cancer Cells
24%
C225
23%
Epidermal Growth Factor
22%
Human Epidermal Growth Factor Receptor 2 (HER2)
21%
Cancer Cells
21%
Hypoxia-inducible factor-1α (HIF-1α)
19%
Paclitaxel
18%
Monoclonal Antibody
18%
Induced Apoptosis
17%
Apoptosis
16%
Tumor
13%
P21Cip1
13%
Anti-epidermal Growth Factor Receptor Antibody
13%
P27Kip1
12%
Growth Inhibition
12%
AKT1
10%
Resection
10%
Gefitinib
9%
In Cancer
9%
Acquired Resistance
9%
Phosphoinositide 3-kinase (PI3K)
9%
Autophagy
9%
Squamous Carcinoma Cells
9%
Constitutively Active
9%
Cytotoxicity
9%
Breast Tumor Kinase
8%
A431 Cells
8%
Human Breast Cancer Cells
8%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
8%
Colorectal Cancer Cells
7%
Radioimmunotherapy
7%
Caspase-8
6%
Antitumor Activity
6%
Induced Growth
6%
G1 Arrest
6%
Kinase Protein
6%
Cyclin-dependent Kinase 2 (CDK2)
6%
Receptor-targeted Therapy
6%
Human Head
6%
Human Neck
6%
Doxorubicin
6%
C-Jun N-terminal Kinase
5%
Trastuzumab
5%
ASCT2
5%
Cytoreduction
5%
Targeted Therapy
5%
Phosphorylation
5%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
59%
Epidermal Growth Factor Receptor
56%
Monoclonal Antibody
27%
Cetuximab
24%
Programmed Cell Death
23%
Phosphotransferase
14%
Kinase
14%
Protein Kinase B
12%
Autophagy
11%
Hypoxia Inducible Factor 1
11%
Epidermal Growth Factor
11%
Growth Inhibition
10%
G1/S Transition
10%
Cytotoxicity
9%
Cyclin-Dependent Kinase
8%
Downregulation
7%
AMP-activated Protein Kinase
7%
Metabolic Pathway
6%
Fibroblast
6%
Serine
6%
Receptor Tyrosine Kinase
6%
Sensitization
6%
Phosphoinositide 3-Kinase
5%
Trastuzumab
5%
Caspase 8
5%
P21
5%
Radiosensitization
5%
Cell Growth
5%
A431 Cells
5%
